Galectin-binding O-glycosylations as regulators of malignancy

Cancer Research

Volumn 75, Issue 16, 2015, Pages 3195-3202

  Dimitroff, Charles J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; GALECTIN; GLYCAN; GLYCOCONJUGATE; GLYCOSIDASE; GLYCOSYLTRANSFERASE; LECTIN; MEMBRANE PROTEIN; PROTEIN SERINE THREONINE KINASE; SELECTIN; SIALYLTRANSFERASE; SULFOTRANSFERASE; BETA-D-GALACTOSIDE ALPHA 2-6-SIALYLTRANSFERASE; POLYSACCHARIDE; PROTEIN BINDING;

BINDING AFFINITY; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; GLYCOSYLATION; HUMAN; LUNG CANCER; MALIGNANT TRANSFORMATION; MELANOMA CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIALYLATION; BIOLOGICAL MODEL; DISEASE COURSE; METABOLISM; NEOPLASM; PATHOLOGY;

DISEASE PROGRESSION; GALECTINS; GLYCOSYLATION; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOPLASMS; POLYSACCHARIDES; PROTEIN BINDING; SIALYLTRANSFERASES;

EID: 84942921705     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0834     Document Type: Review

References (60)

1. Barthel SR, Gavino JD, Descheny L, Dimitroff CJ. Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Ther Targets 2007;11:1473-91.
2. Rabinovich GA, Croci DO. Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012;36:322-35.
3. Hauselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol 2014;4:28.
4. Yang RY, Rabinovich GA, Liu FT. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 2008;10:e17.
5. Tinari N, Kuwabara I, Huflejt ME, Shen PF, Iacobelli S, Liu FT.Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 2001;91:167-72.
6. Ohannesian DW, Lotan D, Lotan R. Concomitant increases in galectin-1 and its glycoconjugate ligands (carcinoembryonic antigen, lamp-1, and lamp-2) in cultured human colon carcinoma cells by sodium butyrate. Cancer Res 1994;54:5992-6000.
7. Earl LA, Bi S, Baum LG. N- and O-glycans modulate galectin-1 binding, CD45 signaling, and T cell death. J Biol Chem 2010;285:2232-44.
8. Hernandez JD, Nguyen JT, He J, Wang W, Ardman B, Green JM, et al. Galectin-1 binds different CD43 glycoforms to cluster CD43 and regulate T cell death. J Immunol 2006;177:5328-36.
9. Agarwal AK, Gude RP, Kalraiya RD. Regulation of melanoma metastasis to lungs by cell surface Lysosome Associated Membrane Protein-1 (LAMP1) via galectin-3. Biochem Biophys Res Commun 2014;449:332-7.
10. Cedeno-Laurent F, Dimitroff CJ. Galectins and their ligands: negative regulators of anti-tumor immunity. Glycoconj J 2012;29:619-25.
11. Croci DO, Cerliani JP, Dalotto-Moreno T, Mendez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 2014;156:744-58.
12. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245-52.
13. Jouve N, Despoix N, Espeli M, Gauthier L, Cypowyj S, Fallague K, et al. The involvement of CD146 and its novel ligand Galectin-1 in apoptotic regulation of endothelial cells. J Biol Chem 2013;288:2571-9.
14. Kopitz J, von Reitzenstein C, Burchert M, CantzM, GabiusHJ. Galectin-1 is amajor receptor for ganglioside GM1, a product of the growth-controlling activity of a cell surface ganglioside sialidase, on human neuroblastoma cells in culture. J Biol Chem 1998;273:11205-11.
15. Griffioen AW, Thijssen VL. Galectins in tumor angiogenesis. Ann Translational Med 2014;2:90.
16. Thijssen VL, Rabinovich GA, Griffioen AW. Vascular galectins: regulators of tumor progression and targets for cancer therapy. Cytokine Growth Factor Rev 2013;24:547-58.
17. Harduin-Lepers A, Krzewinski-Recchi MA, Colomb F, Foulquier F, Groux- Degroote S, Delannoy P. Sialyltransferases functions in cancers. Front Biosci 2012;4:499-515.
18. Rabinovich GA, van Kooyk Y, Cobb BA. Glycobiology of immune responses. Ann N Y Acad Sci 2012;1253:1-15.
19. van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol 2008;9:593-601.
20. Rabinovich GA, Baum LG, Tinari N, Paganelli R, Natoli C, Liu FT, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002;23:313-20.
21. Valenzuela HF, Pace KE, Cabrera PV, White R, Porvari K, Kaija H, et al. Oglycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res 2007;67:6155-62.
22. Roberts AA, Amano M, Felten C, Galvan M, Sulur G, Pinter-Brown L, et al. Galectin-1-mediated apoptosis in mycosis fungoides: the roles of CD7 and cell surface glycosylation. Mod Pathol 2003;16:543-51.
23. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996; 56:4530-4.
24. Skrincosky DM, Allen HJ, Bernacki RJ. Galaptin-mediated adhesion of human ovarian carcinoma A121 cells and detection of cellular galaptinbinding glycoproteins. Cancer Res 1993;53:2667-75.
25. Srinivasan N, Bane SM, Ahire SD, Ingle AD, Kalraiya RD. Poly N-acetyllactosamine substitutions on N- and not O-oligosaccharides or Thomsen- Friedenreich antigen facilitate lung specific metastasis of melanoma cells via galectin-3. Glycoconj J 2009;26:445-56.
26. Yazawa EM, Geddes-Sweeney JE, Cedeno-Laurent F, Walley KC, Barthel SR, Opperman MJ, et al. Melanoma cell galectin-1 ligands functionally correlate with malignant potential. J Invest Dermatol 2015;135:1849-62.
27. Hirabayashi J, Hashidate T, Arata Y, Nishi N, Nakamura T, Hirashima M, et al. Oligosaccharide specificity of galectins: a search by frontal affinity chromatography. Biochim Biophys Acta 2002;1572:232-54.
28. Stowell SR, Arthur CM, Mehta P, Slanina KA, Blixt O, Leffler H, et al. Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens. J Biol Chem 2008;283:10109-23.
29. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-99.
30. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, et al. Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancerassociated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem 2007;282:773-81.
31. Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, et al. Circulating galectin-3 promotesmetastasis by modifyingMUC1localization on cancer cell surface. Cancer Res 2009;69:6799-806.
32. Kudelka MR, Ju T, Heimburg-Molinaro J, Cummings RD. Simple sugars to complex disease-mucin-type o-glycans in cancer. Adv Cancer Res 2015; 126:53-135.
33. Kurosawa N, Kojima N, Inoue M, Hamamoto T, Tsuji S. Cloning and expression of Gal beta 1, 3GalNAc-specific GalNAc alpha 2, 6-sialyltransferase. J Biol Chem 1994;269:19048-53.
34. Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin- Lepers A, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 2004; 64:7050-7.
35. Harduin-Lepers A, Stokes DC, Steelant WF, Samyn-Petit B, Krzewinski- Recchi MA, Vallejo-Ruiz V, et al. Cloning, expression and gene organization of a human Neu5Ac alpha 2-3Gal beta 1-3GalNAc alpha 2, 6-sialyltransferase: hST6GalNAcIV. Biochem J 2000;352:37-48.
36. Tsuchida A, Ogiso M, Nakamura Y, Kiso M, Furukawa K, Furukawa K. Molecular cloning and expression of human ST6GalNAc III: restricted tissue distribution and substrate specificity. J Biochem 2005;138: 237-43.
37. Okajima T, Chen HH, Ito H, Kiso M, Tai T, Furukawa K, et al. Molecular cloning and expression of mouse GD1alpha/GT1aalpha/GQ1balpha synthase (ST6GalNAc VI) gene. J Biol Chem 2000;275:6717-23.
38. Okajima T, Fukumoto S, Ito H, Kiso M, Hirabayashi Y, Urano T, et al. Molecular cloning of brain-specific GD1alpha synthase (ST6GalNAc V) containing CAG/Glutamine repeats. J Biol Chem 1999;274:30557-62.
39. Moody AM, Chui D, Reche PA, Priatel JJ, Marth JD, Reinherz EL. Developmentally regulated glycosylation of the CD8alphabeta coreceptor stalk modulates ligand binding. Cell 2001;107:501-12.
40. Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, et al. An alpha2, 3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 1999;9:1307-11.
41. Julien S, Videira PA, Delannoy P. Sialyl-tn in cancer: (how) did wemiss the target? Biomolecules 2012;2:435-66.
42. Ju T, Wang Y, Aryal RP, Lehoux SD, Ding X, Kudelka MR, et al. Tn and sialyl- Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clin Appl 2013;7:618-31.
43. Ju T, Aryal RP, Kudelka MR, Wang Y, Cummings RD. The Cosmc connection to the Tn antigen in cancer. Cancer Biomark 2014;14:63-81.
44. Julien S, Adriaenssens E, Ottenberg K, Furlan A, Courtand G, Vercoutter- Edouart AS, et al. ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumourigenicity. Glycobiology 2006;16:54-64.
45. Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression. Biochim Biophys Acta 2014;1840:2752-64.
46. Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T. The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-beta secretion from monocytes/macrophages through the DAP12-Syk pathway. Glycobiology 2013;23:178-87.
47. Reticker-Flynn NE, Bhatia SN. Aberrant glycosylation promotes lung cancer metastasis through adhesion to galectins in the metastatic niche. Cancer Discov 2014;5:168-81.
48. Murugaesu N, Iravani M, vanWeverwijk A, Ivetic A, Johnson DA, Antonopoulos A, et al. An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor. Cancer Discov 2014;4:304-17.
49. Kopitz J, von Reitzenstein C, Andre S, Kaltner H, Uhl J, Ehemann V, et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 2001;276:35917-23.
50. Kopitz J, Ballikaya S, Andre S, Gabius HJ. Ganglioside GM1/galectindependent growth regulation in human neuroblastoma cells: special properties of bivalent galectin-4 and significance of linker length for ligand selection. Neurochem Res 2012;37:1267-76.
51. Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. Blood 2010;115:3939-48.
52. Reticker-Flynn NE, Malta DF, Winslow MM, Lamar JM, Xu MJ, Underhill GH, et al. A combinatorial extracellular matrix platform identifies cellextracellular matrix interactions that correlate with metastasis. Nat Commun 2012;3:1122.
53. Krishnan V, Bane SM, Kawle PD, Naresh KN, Kalraiya RD. Altered melanoma cell surface glycosylation mediates organ specific adhesion and metastasis via lectin receptors on the lung vascular endothelium. Clin Exp Metastasis 2005;22:11-24.
54. Dimitroff CJ. Leveraging fluorinated glucosamine action to boost antitumor immunity. Curr Opin Immunol 2013;25:206-13.
55. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res 2009;344:1788-91.
56. Ito K, Scott SA, Cutler S, Dong LF, Neuzil J, Blanchard H, et al. Thiodigalactoside inhibits murine cancers by concurrently blocking effects of galectin-1 on immune dysregulation, angiogenesis and protection against oxidative stress. Angiogenesis 2011;14:293-307.
57. Giguere D, Bonin MA, Cloutier P, Patnam R, St-Pierre C, Sato S, et al. Synthesis of stable and selective inhibitors of human galectins-1 and -3. Bioorg Med Chem 2008;16:7811-23.
58. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxiadriven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 2012;209:1985-2000.
59. Ouyang J, Plutschow A, Pogge von Strandmann E, Reiners KS, Ponader S, RabinovichGA, et al.Galectin-1 serumlevels reflect tumor burden andadverse clinical features in classical Hodgkin lymphoma. Blood 2013;121:3431-3.
60. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013;19:5300-9.